A comparison between entecavir and tenofovir in chronic hepatitis B in the clinical practice: a single-center experience
Chronic Hepatitis B (CHB) affects 350-400 million of patients worldwide. Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are two nucleoside/nucleotide analogs recommended as first-line treatments in CHB. This retrospective study aimed at comparing effectiveness and renal safety of ETV and TD...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SEEd
2015-06-01
|
| Edice: | Clinical Management Issues |
| Témata: | |
| On-line přístup: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1191 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|